Back to top
more

PTC Therapeutics (PTCT)

(Delayed Data from NSDQ)

$78.98 USD

78.98
2,870,286

+0.45 (0.57%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $78.92 -0.06 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Implied Volatility Surging for PTC Therapeutics (PTCT) Stock Options

by Zacks Equity Research

PTC Therapeutics (PTCT) needs investors to pay close attention to the stock based on moves in the options market lately.

    Zacks Equity Research

    3 Reasons Momentum Stock Investors Will Love PTC Therapeutics (PTCT)

    by Zacks Equity Research

    PTC Therapeutics (PTCT) stock is looking quite impressive for momentum-oriented investors as it has favorable price performance and is also seeing positive estimate revisions.

      Zacks Equity Research

      PTC Therapeutics (PTCT) Jumps: Stock Rises 12.9%

      by Zacks Equity Research

      The shares of PTC Therapeutics (PTCT) rose nearly 13% yesterday.

        Zacks Equity Research

        Catabasis' DMD Candidate Slows Disease Progression, Stock Up

        by Zacks Equity Research

        Catabasis' (CATB) edasalonexent achieved sustained disease-modifying effects and slowing of progression of duchenne muscular dystrophy in a phase II study.

          Zacks Equity Research

          The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO

          by Zacks Equity Research

          The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO

            Zacks Equity Research

            PTC Therapeutics, Inc. (PTCT) in Focus: Stock Moves 14.6% Higher

            by Zacks Equity Research

            PTC Therapeutics, Inc. (PTCT) saw its shares rise nearly 15% on the day.

              Zacks Equity Research

              Here's Why Sarepta Stock is Up More Than 60% So Far in 2017

              by Zacks Equity Research

              Sarepta (SRPT) shares have been on an uptrend so far this year, fueled by its DMD drug, Exondys 51's strong performance. The settlement of a patent litigation also boosted the stock.

                Zacks Equity Research

                Implied Volatility Surging for PTC Therapeutics (PTCT) Stock Options

                by Zacks Equity Research

                Investors need to pay close attention to PTC Therapeutics (PTCT) stock based on the movements in the options market lately.

                  Zacks Equity Research

                  Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017

                  by Zacks Equity Research

                  We issued an updated research report on Cambridge, MA-based Sarepta Therapeutics, Inc. (SRPT) on Jun 28.

                    Zacks Equity Research

                    Zacks.com featured highlights: PTC Therapeutics, Catalyst Biosciences, U.S. Silica Holdings, DXC Technology and Patterson-UTI Energy

                    by Zacks Equity Research

                    Zacks.com featured highlights: PTC Therapeutics, Catalyst Biosciences, U.S. Silica Holdings, DXC Technology and Patterson-UTI Energy